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Abstract
Background: Stereotactic radiosurgery (SRS) is an effective treatment for trigeminal neuralgia (TN). Nevertheless, a
proportion of patients will experience recurrence and treatment-related sensory disturbances. In order to evaluate
the predictors of efficacy and safety of image-guided non-isocentric radiosurgery, we analyzed the impact of
trigeminal nerve volume and the nerve dose/volume relationship, together with relevant clinical characteristics.
Methods: Two-hundred and ninety-six procedures were performed on 262 patients at three centers. In 17 patients
the TN was secondary to multiple sclerosis (MS). Trigeminal pain and sensory disturbances were classified according
to the Barrow Neurological Institute (BNI) scale. Pain-free-intervals were investigated using Kaplan Meier analyses.
Univariate and multivariate Cox regression analyses were performed to identify predictors.
Results: The median follow-up period was 38 months, median maximal dose 72.4 Gy, median target nerve volume
25 mm3, and median prescription dose 60 Gy. Pain control rate (BNI I-III) at 6, 12, 24, 36, 48, and 60 months were
96.8, 90.9, 84.2, 81.4, 74.2, and 71.2%, respectively. Overall, 18% of patients developed sensory disturbances. Patients
with volume ≥ 30 mm3 were more likely to maintain pain relief (p = 0.031), and low integral dose (< 1.4 mJ) tended
to be associated with more pain recurrence than intermediate (1.4–2.7 mJ) or high integral dose (> 2.7 mJ; low vs.
intermediate: log-rank test, χ2 = 5.02, p = 0.019; low vs. high: log-rank test, χ2 = 6.026, p = 0.014). MS, integral dose,
and mean dose were the factors associated with pain recurrence, while re-irradiation and MS were predictors for
sensory disturbance in the multivariate analysis.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: alfredo.conti2@unibo.it
†Alfredo Conti, Gueliz Acker, Carolin Senger and Pantaleo Romanelli
contributed equally to this work.
1Department of Neurosurgery, Charité - Universitätsmedizin Berlin, corporate
member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin
Institute of Health, Charitéplatz 1, 10117 Berlin, Germany
2Charité CyberKnife Center, Charité - Universitätsmedizin Berlin,
Augustenburger Platz 1, Berlin 13353, Germany
Full list of author information is available at the end of the article
Conti et al. Radiation Oncology          (2020) 15:115 
https://doi.org/10.1186/s13014-020-01535-1
(Continued from previous page)
Conclusions: The dose to nerve volume ratio is predictive of pain recurrence in TN, and re-irradiation has a major
impact on the development of sensory disturbances after non-isocentric SRS. Interestingly, the integral dose may
differ significantly in treatments using apparently similar dose and volume constraints.
Keywords: CyberKnife, Neuropathic pain, Stereotactic radiosurgery, Trigeminal neuralgia, Neuropathic pain
Background
Trigeminal neuralgia (TN) is the most common cranio-
facial pain syndrome. Medical therapy, usually based on
carbamazepine, is the first treatment option, but effect-
ive pain control often requires doses associated with se-
vere side effects. Surgical treatment option is considered
when drug therapy deems ineffective in controlling pain
and/or causes severe side effects [1]; thus, surgery is
often necessary. In case of a neurovascular conflict, the
first line treatment is microvascular decompression
(MVD), which can result in up to 100% initial pain relief
[2–5]. Nonetheless, this technique is not always applic-
able due to a lack of neurovascular conflict, contraindi-
cations for major surgery, or patient preference.
Alternative techniques aim to modulate the trigeminal
nociceptive pathways either by percutaneous lesioning of
the Gasserian ganglion or by irradiation of the cisternal
portion of the nerve using stereotactic radiosurgery
(SRS) [1, 6, 7]. Clinical experience regarding TN treat-
ment using SRS is based mainly on single isocenter
Gamma knife radiosurgery (GKS) treatments [8]. Typic-
ally GKS results in up to 92% pain relief within 12
months; however, the pain relapse rate during follow-up
is remarkable [9–17]. Alternatively, radiosurgical rhizot-
omy can be performed using a frameless image-guided
robotic technique with the CyberKnife system (CKS) to
irradiate an individually contoured segment of the tri-
geminal nerve by delivering non-isocentric radiation
beams [18–20]. So far, reported clinical results of CKS
seem to be satisfactory, with initial pain relief reported
in 67.0 to 97.8% of the patients [7, 21, 22]. As with the
GKS series, pain relapse is the major pitfall of the radio-
surgical treatments, with pain control decreasing over
time [7]. The ratio of dose to nerve volume, smaller
nerve volume, and low prescribed dose have been
claimed as potential predictors for treatment failure after
SRS [7, 23, 24]; however, large cohort studies analyzing
radiation metric factors interfering with the outcome in
non-isocentric SRS for TN are yet to be reported. Thus,
there is a lack of evidence for standardized therapy algo-
rithms that include the selection of relevant radiosurgi-
cal treatment parameters such as dose to the target,
target nerve volume, and prescription isodose.
The aim of our study was to evaluate predictors of effi-
cacy and safety of image-guided robotic radiosurgery in
a large multicentric patient cohort.
Methods
Setting and study design
The patient data were retrospectively analyzed; thus, con-
sent forms were deemed unnecessary. Data were pooled
from two Italian (centers A and B: CDI Centro Diagnostico
Italiano, Milan and Department of Radiation Oncology,
University of Messina, Messina) and one German (center
C: CyberKnife Center, Charité - Universitätsmedizin Berlin)
centers. The retrospective analysis was approved by the
Ethics Committee Campus Charité Mitte (EA1/233/18)
and by Comitato Etico Interaziendale Messina (80/19).
Participants
Patients with TN, as defined by the International Head-
ache Society (2003), who were treated using non-
isocentric, image-guided robotic radiosurgery for medic-
ally resistant pain between 2010 and 2016 (center A),
2013–2018 (center B), and 2011–2018 (center C) were
included in this study.
Variables
We gathered data regarding the presence of multiple scler-
osis (MS), re-irradiation, decision making for SRS, clinical
outcome, and therapy-associated morbidity with a focus
on sensory dysfunctions. Mean and maximal treatment
dose (Dmean, Dmax), target nerve volume, prescription dose
(PD), and integral dose (ID, calculated as target nerve vol-
ume × mean dose) were the parameters investigated.
Radiosurgery treatment
Patients were treated with SRS using a CyberKnife sys-
tem (Accuray Inc., Sunnyvale, California) as described
before [7]. The treatment was planned using MultiPlan
(Accuray Inc.) on a native computed tomography (CT)
scan (120 kV, slice thickness: ≤ 1.0 mm) and co-
registered constructive interference in steady state
(CISS) magnetic resonance (MR) images (T2-weighted,
3D gradient echo technique, isotropic voxel size: ≤ 1.0 ×
1.0 × 1.0 mm3) (Fig. 1). The target nerve volume includes
the complete nerve diameter over an interindividual
nerve length, typically 5–6 mm of the cisternal portion
of the trigeminal nerve outlined, depending on the pa-
tient’s anatomy. The 80% isodose line was then pre-
scribed, encompassing the contoured nerve volume
between the root entry zone and the area where the
nerve leaves the intracranial space to enter the Meckel’s
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cave, while keeping a certain distance to the brainstem
and temporal lobe. The treatment dose was selected ac-
cording to each hospital standard. Dose constraints to
organs at risk (OAR) were as follows: < 0.50 cm3 of the
brainstem was allowed to receive 10.0 Gy with a max-
imum dose of 15.0 Gy in ≤0.035 cm3 and ≤ 0.035 cm3 of
the temporal lobe was allowed to receive a maximum
dose of 35.0 Gy. Treatment dose or volume was adjusted
if the OAR constraints were not applicable due to indi-
vidual trigeminal nerve anatomy or cisternal narrowness.
Treatment planning, determination of target and dose,
and treatment delivery are described in detail in
Additional file 1.
Outcome assessment
Clinical follow-up was carried out 3–6months after CK-
SRS and then once yearly. The latest follow-up was included
in this study. The focus of the follow-up was to verify the
pain relief and new onset of facial numbness; accordingly,
the endpoints analyzed were: i) pain relief, ii) occurrence of
sensory disturbance, and iii) rate of pain recurrence.
Quantitative variables
Pain and hypoesthesia evaluation were scored using the
Barrow Neurological Institute (BNI) scales for pain I-V
and for hypoesthesia I-IV, respectively [25]. We dichoto-
mized the pain response as sufficient or inadequate after
treatment as BNI grades I-IIIb and IV-V, respectively.
Similarly, non-significant or bothersome numbness were
categorized as BNI grades I-II and III-IV, respectively.
Any consecutive trigeminal motor deficits were recorded.
Statistical methods
Overall, the entire pain-free interval was examined using
Kaplan Meier analysis. Pain-free intervals for 6, 12, 24,
36, 48, and 60months were calculated. Group compari-
son was carried out using the log-rank test. In order to
assess risk factors potentially associated with pain
relapse or occurrence of numbness, univariate and
multivariate Cox regression analyses were performed
using clinically selected variables. The selection process
of variables for the multiple regression model included
two steps as described before [26].
The treatment parameters were reported as mean
(standard deviation [SD]) and median. SPSS version 25.0.
(Armonk, NY; IBM Corp.) was used for statistical analyses.
As this was an exploratory study where a series of group
comparisons, regression analyses, and tests of normal distri-
bution for continuous variables were performed, the two-
sided p-values, described as significant if < 0.05, are meant
as indicators and should not be interpreted as confirmatory.
Results
Participants
Patient characteristics are listed in Table 1. A total of 296
TN treatments in 262 patients were included in the ana-
lysis. Center A included 144 patients (55%), center B in-
cluded 79 patients (30.2%), and center C included 39
patients (14.8%). Accordingly, 34 patients (13%) needed
CyberKnife-SRS re-irradiation. We analyzed the decision-
making process for selecting CyberKnife-SRS instead of
MVD. The most crucial reasons were missing nerve/vessel
conflicts on MR images and age of the patients (age ≥ 75
years), followed by personal preference (Fig. 2).
There was overall a minor female predominance (1.4:1.0).
MS was diagnosed in 6.5% (n = 17) of the patients. The me-
dian age at therapy was 64 years (range 22–91 years).
A follow-up with at least 3 months intervals was pos-
sible in 96% of the cases. The median follow-up time to
last contact was 38 months (range 0.7–117 months).
Main results
Radiosurgical parameters
The treatment plans and target nerve volume, PD,
Dmean, Dmax, and ID data for the three different institu-
tions are summarized in Table 2. The treatment
Fig. 1 Typical CyberKnife stereotactic dose distribution for trigeminal neuralgia targeted at the cisternal portion of the nerve. left: MR CISS
weighted axial image, middle and right: sagittal and coronal CT images. The dose is typically 60 Gy prescribed to the 80% isodose line
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parameters were overall comparable in the three centers,
with differences in volume, Dmax, and ID.
Response of TN to primary CKS
For this analysis, we focused on the response to the first
SRS treatment and excluded the retreated patients. Ac-
tuarial pain control rates could be acquired in 88.2% of
the cases (231 patients). In 54.1% of the patients, full
pain control (BNI I) could be achieved (Table 3). Esti-
mated pain control rates (BNI class I-III) at 6, 12, 24, 36,
48, and 60months were 96.8, 90.9, 84.2, 81.4, 74.2, and
71.2%, respectively (Fig. 3). Facial numbness as a side ef-
fect occurred in 18% of patients.
Re-irradiation
We identified 34 SRS re-irradiations in our cohort. None
of the retreated patients had MS. The majority of the pa-
tients (70%) suffered from new onset numbness after re-
irradiation. Actuarial pain control rates (BNI class I-III)
for re-irradiation at 6, 12, 24, 36, 48, and 60months
were 91.2, 88.1, 88.1, 88.1, 79.8, and 79.8%, respectively
(Fig. 3). There was, however, no statistically significant
difference compared to primary therapy.
Predictors for treatment outcome
Pain relief
Univariate Cox regression analyses showed that lower
ID, smaller nerve volume, and presence of MS were as-
sociated with treatment failure (Table 4). With regard to
multicollinearity, we had to decide between Dmean, Dmax,
ID, and volume for inclusion in the multivariate analysis.
We chose mean ID based on clinical interest. In multi-
variate analysis, lower ID and presence of MS were the
major predictors for treatment failure, while higher
mean dose also emerged as a significant predictor with a
slightly higher risk for pain recurrence. With regard to
pain as the outcome, the multivariate Cox regression
model was comparable when patients with re-irradiation
and/or MS were excluded (ID: hazard ratio [HR] = 0.517,
confidence interval [CI] = 0.354–0.756); Dmean: HR =
Table 1 Patient demographic characteristics
Total Center A Center B Center C
Treatments (Patients) 296 (262) 176 (144) 80 (79) 40 (39)
Sex
Male 42.9% 44.3% 42.5% 37.5%
Female 57.1% 55.7% 57.5% 62.5%
Age at treatment (years)
Median (range) 63.8 (22.4–91.4) 60.5 (22.4–89.2) 66.9 (40.7–88.1) 66.1 (40.9–91.4)
Follow-up (months)
Mean (SD) 40.7 (29.0) 38.4 (20.4) 58.3 (36.6) 16.4 (16.6)
Median (range) 38.0 (0.7–117.0) 38.4.0 (3.7–79.3) 49.0 (3.0–117.0) 8.0 (0.7–66.1)
Re-irradiation (n) 34 32 1 1
MS (n) 17 8 0 9
Fig. 2 An overview of the indications for CyberKnife stereotactic radiosurgery instead of microvascular decompression (MVD)
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1.038, CI = 0.999–1.079). The probability of maintaining
pain relief was then compared according to the catego-
rized treatment parameters (Table 4): volume (<30 vs.
≥30mm3), ID (< 1.4, 1.4–2.7, > 2.7mJ), Dmean (< 63 vs.
≥ 63Gy), Dmax (< 72 vs. ≥ 72Gy), and PD (< 58 vs. ≥ 58
Gy). Here, only the volume and ID comparisons resulted in
significant differences. Patients with volume above 30mm3
were less likely to experience pain recurrence (< 30 vs.
≥ 30mm3; χ2 = 4.675, p = 0.031, Table 4; Fig. 4a), while pa-
tients with low ID (< 1.4mJ) tended to suffer more and
earlier pain recurrence compared to intermediate (1.4–2.7
mJ) or high ID (> 2.7mJ) patients (low vs. intermediate:
log-rank test, χ2 = 5.020, p = 0.019; low vs. high: log-rank
test, χ2 = 6.026 p = 0.014; Table 5, Fig. 4b).
Occurrence of sensory disturbances
Re-irradiation using CyberKnife-SRS and presence of
MS were independent predictors for the development of
bothersome post-treatment numbness in the univariate
and multivariate analysis. We also detected a minor but
still significant association of isodose in the univariate
analysis (Table 6). As with the pain relief analysis, we
chose to assess Dmean in the multivariate analysis and
had to exclude Dmax due to multicollinearity. When pa-
tients with re-irradiation and/or MS were excluded, the
multivariate model showed slight adjustments in the HR
estimators. Isodose became a significant predictor vari-
able with a weak influence (Isodose: HR = 1.097, CI =
1.004–1.198, p = 0.041).
Discussion
Key results
This study was aimed at identifying irradiation parameters
that may predict efficacy and safety of image-guided non-
isocentric radiosurgery for treatment of TN. For this pur-
pose, we analyzed the impact of target nerve volume, target
dose, and the dose/volume relationship, together with rele-
vant clinical characteristics, in a large multicenter
German-Italian cohort of patients with a follow-up interval
of up to 10 years. As expected, smaller target volume and
lower ID were associated with worse pain outcome. In par-
ticular, we suggest that a target volume around 30mm3
and an ID > 1.4mJ offer better outlooks of sustained pain
control. MS as a cause of TN was an independent prog-
nosticator of treatment failure and shorter pain free inter-
val. Furthermore, re-irradiation and presence of MS were
independent predictors of the occurrence of numbness.
The results of this series in terms of pain relief are
consistent with those previously reported and suggest
that image-guided robotic radiosurgery represents an ef-
fective treatment of TN [7, 8, 10, 17]. Our results are in-
deed slightly superior to those previously published by
Romanelli et al. (n = 138 pts.), who reported 76% pain
relief after 3 years compared to 81.4% in the present co-
hort [7]. This comparison remained the same with the
more recent series by Romanelli et al., with 76% pain
relief at 36 months [27]. Furthermore, we here report re-
sults with longer follow-up and describe actuarial pain
control rates (BNI class I-III) at 6, 12, 24, 36, 48, and 60
months of 96.8, 90.9, 84.2, 81.4, 74.2, and 71.2%, re-
spectively (Fig. 2). With regard to sensory distur-
bances, facial numbness was reported by 18% of
patients, with < 1% reporting bothersome hypoesthe-
sia. Our results are also similar to those published
by the two largest studies on GKS [10, 17]. In
Table 2 Summary of treatment parameters in the three centers
n Mean (SD) Median Min Max
Volume (mm3) Center A 176 29.0 (14.3) 25.0 5.0 103.3
Center B 80 27.7 (12.3) 30.0 10.0 70.0
Center C 40 23.8 (12.8) 20.0 10.0 60.5
Overall 296 28.0 (13.7) 25.0 5.0 103.3
Prescription dose (Gy) Center A 176 57.7 (6.7) 60.0 35.0 90.0
Center B 80 57.4 (2.6) 58.0 38.0 60.0
Center C 40 60.2 (4.1) 60.0 49.0 70.0
Overall 296 58.0 (5.6) 60.0 35.0 90.0
Isodose (%) Center A 176 83.0 (3.2) 83.0 73.0 90.0
Center B 80 80.0 (0.4) 80.0 78.0 80.0
Center C 40 80.0 (3.2) 80.0 70.0 85.0
Overall 296 81.6 (3.1) 80.0 70.0 90.0
Dmax (Gy) Center A 176 70.0 (8.1) 71.3 42.7 112.5
Center B 80 72.0 (3.3) 72.5 47.5 75.0
Center C 40 75.7 (4.0) 75.0 70.0 87.5
Overall 296 71.1 (7.0) 72.4 42.7 112.5
Dmean (Gy) Center A 176 63.7 (7.3) 65.3 38.8 101.3
Center B 80 64.7 (2.9) 65.3 42.8 67.5
Center C 40 68.1 (3.8) 67.5 59.8 80.1
Overall 296 64.5 (6.2) 65.3 38.8 101.3
Integral dose (mJ) Center A 176 2.0 (0.9) 1.6 0.3 6.7
Center B 80 1.8 (0.8) 1.9 0.6 4.4
Center C 40 1.6 (0.8) 1.4 0.7 4.0
Overall 296 1.8 (0.9) 1.6 0.3 6.7
Table 3 Summary of actuarial pain control classified on the
Barrow Neurological Institute (BNI) pain scale in 231 patients







Grades III a and b were combined
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particular, Regis et al. have recently published the
long-term results of 497 patients with the probability
pain relief at 6 months and 1, 2, 3, 5, 7, and 10 years
of 94.3, 90.2, 87.7, 83.6, 80.3, 75.4, and 67.7%, re-
spectively, and a rate of new sensory disturbances of
20.4% [28].
Interpretation
Tuleasca et al. summarized various treatment regimens
regarding dose and target delineation of SRS in the
treatment of TN [8]. Romanelli et al. was the first to re-
port the use of frameless and non-isocentric SRS as a
treatment option for TN [29]. They reported high
Fig. 3 Pain relief Kaplan Meier curves for primary and re-irradiation treatments
Table 4 Univariate and multivariate Cox regression analyses for factors affecting pain outcome
Univariate Analyses Multivariate Analysis
HR 95% CI p-value HR 95% CI p-value
Age 0.994 0.977–1.011 0.491
Gender 1.195 0.725–1.970 0.484
Volume 0.956 0.933–0.980 0.000
Integral dose 0.549 0.381–0.792 0.001 0.540 0.376–0.775 0.001
Dmean 1.027 0.987–1.068 0.189 1.041 1.002–1.080 0.038
Isodose 0.988 0.908–1.075 0.777
Dmax 1.026 0.991–1.062 0.150








0.340 0.162–0.714 0.004 0.332 0.156–1.002 0.004
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precision and almost immediate pain relief following
treatment with a PD between 65 and 70 Gy on a nerve
segment up to 11 mm [29]. However, the irradiation of
such long nerve segments led to a significant numbness
in these patients; thus, new therapeutic algorithms were
explored to identify the best treatment parameters.
In 2008 Villavicencio et al. [22] published the evalu-
ation of 95 patients who were treated using CyberKnife-
SRS. The authors included not only heterogeneous treat-
ments in this study concerning dose and target volumes,
but also modalities like isocentric and non-isocentric.
The median maximal dose used was 75 Gy. Some var-
iables were predictive for pain recurrence, such as
median maximum and minimum dose and targeted
median nerve length. In this cohort, 50% of the popu-
lation had good pain control after 2 years, but 47% of
the patients developed new facial numbness [22].
Thus, the irradiation of a long trigeminal nerve seg-
ment led to a very good rate of pain control, but also
to a significant risk of facial numbness and suggested
the necessity to set precise dose/volume constraints
to optimize treatments.
Romanelli et al. have recently found a shorter treated
nerve length (< 6 vs. 6 mm), a smaller treated nerve vol-
ume (< 30 vs. > 30 mm3), and a lower PD (< 58 vs. > 58
Gy) as predictors for treatment failure in univariate ana-
lysis, while none of these factors remained significant in
multivariate analysis [7]. Those results were integrated
into a larger and multicentric population of patients to
improve the reliability and reproducibility of the find-
ings. In the present univariate analysis, target nerve vol-
ume, ID, and presence of MS turned out to be factors
associated with pain recurrence. ID and MS also
retained significance in the multivariate analysis, while
volume could not be included because of high correl-
ation with ID. Our results support the impact of MS on
the outcome of patients with TN, consistent with our
previous study where only 44% of patients were pain-
free for years after therapy [30]. This present study con-
firmed that patients with nerve volumes < 30mm3 were
more likely to suffer pain relapse. In addition, this was
also observed for patients with low ID (< 1.4 mJ). The ID
is the product of the mean dose and the target nerve
volume and therefore represents an ideal parameter for
Fig. 4 Kaplan Meier comparisons of pain-freedom probability. a target volume (< 30 mm3 vs. ≥ 30 mm3) and (b) integral dose (< 1.4 mJ;
1,4–2,7 mJ; > 2,7 mJ)
Table 5 Comparisons of binarized treatment parameters for the probability of maintaining pain relief
Variables n Chi2 and P-values
Pain
Volume (< 30 vs. ≥ 30 mm3) 205 vs. 91 χ2 = 4.675, p = 0.031
Integral dose (< 1.4, 1.4–2.7, > 2.7 mJ) 114 vs. 144 vs. 39 low vs. intermediate: χ2 = 5.020, p = 0.019
low vs. high: χ2 = 6.026, p = 0.014
intermediate vs. high, χ2 = 0.221, p = 0.638
Dmean (< 63 vs. ≥ 63 Gy) 75 vs. 221 χ
2 = 1.803, p = 0.179
Dmax (< 72 vs. ≥ 72 Gy) 132 vs. 164 χ
2 = 2.756, p = 0.097
Prescriptin dose (< 58 vs. ≥ 58 Gy) 130 vs. 166 χ2 = 0.440, p = 0.838
p < 0.05 - significant, log-rank test. χ2 - test statistic of the Chi2 test
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non-isocentric treatments in which not only the dose,
but also the target volume can be modulated to fit indi-
vidual anatomy and clinical objectives. Mousavi et al.
[23] investigated 155 patients treated by GKS and re-
ported that the optimal treatment outcome could be
achieved by medium IDs (1.4–2.7 mJ). To be able to
compare our cohort with the study by Mousavi et al.
[23], we categorized the ID in the same way and ob-
served that the patients with lower IDs (i.e. < 1.4 mJ)
were more likely to suffer pain relapse. This is in line
with our finding that lower ID was an independent pre-
dictor for pain recurrence in this analysis. One treatment
parameter which has been associated with the clinical
outcome, particularly to the risk of sensory disturbance,
is the dose received by the brainstem [21, 31].
Finally, we identified re-irradiation as the major inde-
pendent predictor for sensory disturbance, with almost a
six times higher risk after CKS as already described by
Romanelli et al. [7] In our univariate analyses, presence
of MS and prescription isodose, in addition to re-
irradiation, were also associated with the development of
sensory disturbances, but only re-irradiation and MS
retained significance in the multivariate analysis as inde-
pendent prognostic factors.
Limitations
Our follow-up length is longer than that of most studies
focusing on the efficacy of SRS in TN published so far
[9–17], but much longer follow-up periods are needed
for a definitive evaluation of the technique. This is in-
deed essential to provide a valid comparison with MVD.
Although we have reported good to excellent outcomes,
long-term results up to 10 years later could be
disappointing, with up to 60% pain recurrence rates at a
later stage [17, 28, 32].
Conclusions
This study represents the largest multicenter frameless
CKS series conducted to analyze possible treatment pa-
rameters as predictors of outcome in addition to the de-
scription of efficacy and safety profile of the technique.
Our study confirmed that single treatment parameters
are not enough to predict treatment efficacy of SRS in
TN. The ID, Dmean, and nerve volume are apparently
relevant, as they may differ significantly in treatments
using apparently similar dose and volume constraints.
Our study supports the concept of personalized radio-
surgery for the best treatment outcome and warrants fu-
ture prospective studies.
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